18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
21:54 , Oct 31, 2018 |  BC Extra  |  Company News

GSK cuts some respiratory targets, keeps others in play

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) cut three respiratory programs against targets largely ignored by the rest of the industry after all three failed to meet efficacy targets in Phase II trials. The pharma disclosed the pruning...
18:00 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round on Oct. 17 led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla...
17:06 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Velicept raises additional $15M in series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised $15 million in a series B round extension led by Samsara BioCapital. Existing investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...
18:23 , Oct 17, 2018 |  BC Extra  |  Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners,...
18:16 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Urovant raises $140 million IPO

Urovant Sciences Ltd. (NASDAQ:UROV), the urology subsidiary of Roivant Sciences GmbH (Basel, Switzerland), raised $140 million late Sept. 26 through the sale of 10 million shares at $14 in an IPO underwritten by J.P. Morgan,...
15:34 , Sep 27, 2018 |  BC Extra  |  Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20...
17:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
16:42 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

AZ says Phase IIIb data of Bevespi Aerosphere in COPD are 'inconsistent with previous data'

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Bevespi Aerosphere glycopyrrolate/formoterol fumarate met one of three primary endpoints in the Phase IIIb AERISTO trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere was...